ScholarIQanswers from OpenAlex
Alector (United States)
InstitutionResearch output, impact & collaborations
Alector (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Alector (United States)?
ScholarIQrecord summary
Alector (United States) is a research organisation in San Francisco, US. OpenAlex records 179 works and 20,612 citations for it. 116 researchers list it as their most recent affiliation.
How many works does Alector (United States) have?
ScholarIQindexed works
Alector (United States) has 179 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Alector (United States) have?
ScholarIQcitation count
Alector (United States) has 20,612 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Alector (United States)?
ScholarIQresearcher count
Alector (United States) has 116 researchers in the ScholarIQ index.
What is the average h-index at Alector (United States)?
ScholarIQavg h-index
Alector (United States) has an average h-index of 71.3 in OpenAlex.
What is the ROR of Alector (United States)?
ScholarIQror
The ROR for Alector (United States) is on the source record.
What is the OpenAlex record for Alector (United States)?
ScholarIQopenalex
The OpenAlex for Alector (United States) is on the source record.
Who are the most-cited researchers behind Alector (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Alector (United States)?
ScholarIQmost cited works
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Alan Sandler, Robert J. Gray, Michael C. Perry, Julie R. Brahmer, Joan H. Schiller, Afshin Dowlati, Rogério Lilenbaum, David H. Johnson
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazières, Keunchil Park, David C. Smith, Á. Artal, C. Lewanski, Fadi Braiteh, Daniel Waterkamp, Pei He, Wei Zou, Daniel S. Chen, Jing Yi, Alan Sandler, Achim Rittmeyer
How much of the research on Alector (United States) is open access?
ScholarIQopen access share
75%OPEN ACCESS